Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 1 test: 1 consistent, 0 inconsistent, 1 via agent-written checks.

1 integrity concern flagged (0 high).

16 copyedit issues flagged: mostly consistency, clarity, punctuation.

Checked 38 references: 31 verified — 7 not checked.

2 data/code links checked; 2 live.

Ready for submission after minor to moderate revisions. The three warn-dimension issues (open-label limitations; p-value reporting and multiplicity; data/code availability) are straightforward to address and do not undermine the study's core conclusions. Authors should prioritize the data availability statement, as this is increasingly a journal requirement.

1. 1.
   HIGHdata code

   Add an explicit data availability statement specifying the repository/platform (e.g., ClinicalStudyDataRequest, Vivli, or an institutional data access committee) and conditions for access, including a timeframe for response.

   The current 'available on reasonable request' statement is vague and fails current journal standards; a concrete pathway is expected for data-driven publications.
2. 2.
   HIGHstatistics

   Report exact p-values (e.g., p=0.032, not p<0.05) for all primary and key secondary efficacy comparisons, or explain why confidence intervals alone suffice per the non-inferiority framework.

   Two reviewers flagged inconsistent p-value reporting; exact values improve transparency and allow readers to assess evidence strength.
3. 3.
   HIGHstatistics

   Explicitly state how multiplicity across the five experimental arms was handled (e.g., hierarchical testing, Bonferroni correction, or a statement that no adjustment was made and why).

   Multiple comparisons without adjustment inflate Type I error; the current footnote in Table 2 does not provide a justification for the approach.
4. 4.
   HIGHrigor

   In the Discussion, expand the justification for the open-label design beyond 'treatment-duration difference' to discuss specific measures taken to mitigate bias (e.g., blinded central outcome adjudication, concealment from laboratory staff).

   Two reviewers considered the blinding rationale insufficient; stronger justification enhances reader confidence in results despite the open-label design.
5. 5.
   HIGHrigor

   Clarify in the Statistical Methods section whether the power analysis covers all five experimental arms or only a subset, and if only a subset, acknowledge the implications for the non-covered arms.

   The power analysis explicitly covers only 3 of 5 regimens in mITT and 2 in PP; readers need to understand which comparisons are adequately powered.
6. 6.
   HIGHstatistics

   Verify and report the proportional hazards assumption for each Cox regression comparison individually (not just globally), or note if it was not tested for each.

   Schoenfeld residuals are mentioned but it is unclear whether they were applied per-regimen; assumption violations can bias hazard ratio estimates.
7. 7.
   MEDIUMdata code

   Deposit the Stata analysis code (e.g., .do files) in a public repository such as GitHub or Zenodo with a persistent identifier, even if patient-level data cannot be shared.

   Code sharing enhances reproducibility; it is independent of data sharing and is increasingly expected by journals.
8. 8.
   MEDIUMreporting

   Add a brief statement in the Statistical Methods about how missing data were handled in the primary analysis (e.g., complete-case analysis, multiple imputation).

   Missing data handling is a key methodological detail that is currently absent; its omission may raise reviewer questions.
9. 9.
   MEDIUMcopyedit

   Add a comma after 'week 73' in the Abstract: '... favorable outcome at week 73, defined by ...'

   Missing comma before 'defined' causes a minor clarity issue in the primary outcome definition.
10. 10.
    MEDIUMcopyedit

    In the Safety Results, add a comma after 'respectively': '... 54/174 (31.0%), respectively, were classified ...'

    Missing comma creates an awkward reading; punctuation fix ensures clarity.
11. 11.
    MEDIUMcopyedit

    Capitalize 'Eastern Cooperative Oncology Group' consistently in Table 1 footnotes.

    Minor capitalization inconsistency as flagged by copyedit.
12. 12.
    LOWreporting

    Consider specifying the years or versions of the WHO guidelines that changed during enrollment in the Discussion.

    Providing guideline version details adds context for readers tracking evolving standards.
13. 13.
    LOWcopyedit

    Rephrase 'for at least rifampin and fluoroquinolones' in Methods for clarity (e.g., 'for rifampin and fluoroquinolones, at a minimum').

    The current phrasing is grammatically awkward and could cause confusion.